NZ594434A - Compositions and methods for the treatment of cancer - Google Patents
Compositions and methods for the treatment of cancerInfo
- Publication number
- NZ594434A NZ594434A NZ594434A NZ59443410A NZ594434A NZ 594434 A NZ594434 A NZ 594434A NZ 594434 A NZ594434 A NZ 594434A NZ 59443410 A NZ59443410 A NZ 59443410A NZ 594434 A NZ594434 A NZ 594434A
- Authority
- NZ
- New Zealand
- Prior art keywords
- inhibitor
- aryl
- alkyl
- cancer
- cellular energy
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 6
- 230000001093 anti-cancer Effects 0.000 abstract 5
- 230000001413 cellular effect Effects 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 229910052783 alkali metal Inorganic materials 0.000 abstract 2
- 150000001340 alkali metals Chemical class 0.000 abstract 2
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 abstract 1
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 150000004703 alkoxides Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000006177 biological buffer Substances 0.000 abstract 1
- 239000006227 byproduct Substances 0.000 abstract 1
- 150000007942 carboxylates Chemical class 0.000 abstract 1
- 230000034659 glycolysis Effects 0.000 abstract 1
- 150000004820 halides Chemical class 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14838509P | 2009-01-29 | 2009-01-29 | |
| PCT/US2010/022664 WO2010088564A2 (en) | 2009-01-29 | 2010-01-29 | Compositions and methods for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ594434A true NZ594434A (en) | 2014-11-28 |
Family
ID=42396378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ594434A NZ594434A (en) | 2009-01-29 | 2010-01-29 | Compositions and methods for the treatment of cancer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8022042B2 (enExample) |
| EP (1) | EP2391363B1 (enExample) |
| JP (2) | JP6068803B2 (enExample) |
| KR (1) | KR20110110355A (enExample) |
| CN (1) | CN102387801A (enExample) |
| AU (1) | AU2010208062B2 (enExample) |
| CA (2) | CA2750944C (enExample) |
| DK (1) | DK2391363T3 (enExample) |
| ES (1) | ES2607211T3 (enExample) |
| HR (1) | HRP20161686T1 (enExample) |
| HU (1) | HUE032389T2 (enExample) |
| IL (1) | IL214349A (enExample) |
| NZ (1) | NZ594434A (enExample) |
| PL (1) | PL2391363T3 (enExample) |
| PT (1) | PT2391363T (enExample) |
| SI (1) | SI2391363T1 (enExample) |
| WO (1) | WO2010088564A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324175B2 (en) | 2006-02-16 | 2012-12-04 | Young Hee Ko | Compositions and methods for the treatment of cancer |
| US8758323B2 (en) | 2009-07-30 | 2014-06-24 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| CN103610671A (zh) * | 2013-12-10 | 2014-03-05 | 江苏长泰药业有限公司 | 丙酮酸药物组成及其在制备治疗肺癌药物中的用途 |
| EP3293167A1 (en) | 2016-09-09 | 2018-03-14 | Université Catholique De Louvain | [18f]-labelled lactate derivative as pet radiotracer |
| US10245235B2 (en) | 2016-12-16 | 2019-04-02 | The Charlotte-Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| US10434113B2 (en) | 2016-12-16 | 2019-10-08 | The Charlotte Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| EP3596043B1 (en) * | 2017-03-15 | 2025-12-03 | Lunella Biotech, Inc. | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast |
| KR20230038212A (ko) * | 2020-06-29 | 2023-03-17 | 코디스커버리, 엘엘씨 | 병원성 감염 치료를 위한 세포 에너지 억제제 제형 및 관련 방법 |
| WO2023196543A2 (en) * | 2022-04-06 | 2023-10-12 | Young Hee Ko | Liquid-dispersible halopyruvate formulations and associated methods |
| CN116375769B (zh) * | 2023-03-10 | 2024-12-03 | 云南贵金属实验室有限公司 | 一种双靶点Pt(Ⅳ)抗癌前药及其制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3360633D1 (en) | 1982-02-12 | 1985-10-03 | Unitika Ltd | Anti-cancer device |
| US5800820A (en) | 1989-01-10 | 1998-09-01 | Repligen Corporation | Methods and compositions for treatment of angiogenic diseases |
| US5759837A (en) | 1989-01-17 | 1998-06-02 | John Hopkins University | Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway |
| US5284786A (en) * | 1992-08-14 | 1994-02-08 | National Semiconductor Corporation | Method of making a split floating gate EEPROM cell |
| US5854067A (en) | 1996-01-19 | 1998-12-29 | Board Of Regents, The University Of Texas System | Hexokinase inhibitors |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| US6284786B1 (en) | 1999-02-16 | 2001-09-04 | The Center For The Improvement Of Human Functioning, Int'l., Inc. | Treatment of cancer using lipoic acid in combination with ascorbic acid |
| US20020006915A1 (en) | 2000-02-15 | 2002-01-17 | Mack Strong Vivian E. | Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation |
| US6448030B1 (en) | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| AU2001245766A1 (en) | 2000-03-14 | 2001-09-24 | The Johns Hopkins University School Of Medicine | Arrest of proliferation of highly glycolytic tumors |
| US6670330B1 (en) | 2000-05-01 | 2003-12-30 | Theodore J. Lampidis | Cancer chemotherapy with 2-deoxy-D-glucose |
| AU2002233916A1 (en) | 2000-08-03 | 2002-04-29 | Albert Einstein College Of Medicine | Isocitrate lyase enzyme from mycobacterium tuberculosis and inhibitory agents to combat persistent infection |
| US7381713B2 (en) | 2000-12-04 | 2008-06-03 | Sioan-Kettering Institute For Cancer Research | Treatment of cancer by reduction of intracellular energy and pyrimidines |
| US7547673B2 (en) | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
| WO2004013307A2 (en) | 2002-08-05 | 2004-02-12 | Mirus Corporation | Compounds for targeting hepatocytes |
| US20040126789A1 (en) | 2002-09-05 | 2004-07-01 | Invitrogen Corporation | Compositions and methods for synthesizing nucleic acids |
| US20040229826A1 (en) * | 2002-12-12 | 2004-11-18 | Larry Norton | Dose-dense & sequential adjuvant cancer chemotherapy |
| AU2004204778B2 (en) * | 2003-01-10 | 2008-05-22 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| US20060172953A1 (en) * | 2003-01-17 | 2006-08-03 | Threshold Pharmaceuticals Inc. | Treatment of benign prostatic hyperplasia using energolytic agents |
| EP1610778A4 (en) | 2003-01-17 | 2006-05-31 | Threshold Pharmaceuticals Inc | TREATMENT OF BENIGNER PROSTATE HYPERPLASIA |
| CA2575367A1 (en) | 2004-07-28 | 2006-02-23 | Board Of Regents, The University Of Texas System | 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| JP2008540566A (ja) * | 2005-05-12 | 2008-11-20 | スレッシュオールド ファーマシューティカルズ， インコーポレイテッド | ２−デオキシグルコースを用いたがんの処置 |
| US7754693B2 (en) * | 2006-02-16 | 2010-07-13 | Young Hee Ko | Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer |
| EP2114413B1 (en) * | 2006-12-18 | 2014-10-22 | The Johns Hopkins University | Therapeutics for treating cancer using 3-bromopyruvate |
-
2010
- 2010-01-29 NZ NZ594434A patent/NZ594434A/en not_active Application Discontinuation
- 2010-01-29 EP EP10736502.5A patent/EP2391363B1/en active Active
- 2010-01-29 HU HUE10736502A patent/HUE032389T2/en unknown
- 2010-01-29 HR HRP20161686TT patent/HRP20161686T1/hr unknown
- 2010-01-29 PL PL10736502T patent/PL2391363T3/pl unknown
- 2010-01-29 US US12/697,169 patent/US8022042B2/en active Active
- 2010-01-29 DK DK10736502.5T patent/DK2391363T3/en active
- 2010-01-29 JP JP2011548359A patent/JP6068803B2/ja active Active
- 2010-01-29 KR KR1020117019808A patent/KR20110110355A/ko not_active Ceased
- 2010-01-29 AU AU2010208062A patent/AU2010208062B2/en not_active Ceased
- 2010-01-29 CA CA2750944A patent/CA2750944C/en active Active
- 2010-01-29 SI SI201031357A patent/SI2391363T1/sl unknown
- 2010-01-29 CA CA3024263A patent/CA3024263A1/en not_active Abandoned
- 2010-01-29 WO PCT/US2010/022664 patent/WO2010088564A2/en not_active Ceased
- 2010-01-29 PT PT107365025T patent/PT2391363T/pt unknown
- 2010-01-29 ES ES10736502.5T patent/ES2607211T3/es active Active
- 2010-01-29 CN CN2010800121947A patent/CN102387801A/zh active Pending
-
2011
- 2011-07-28 IL IL214349A patent/IL214349A/en active IP Right Grant
-
2015
- 2015-06-10 JP JP2015117604A patent/JP2015180680A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6068803B2 (ja) | 2017-01-25 |
| WO2010088564A2 (en) | 2010-08-05 |
| KR20110110355A (ko) | 2011-10-06 |
| US20100197612A1 (en) | 2010-08-05 |
| EP2391363A2 (en) | 2011-12-07 |
| US8022042B2 (en) | 2011-09-20 |
| JP2012516358A (ja) | 2012-07-19 |
| HRP20161686T1 (hr) | 2017-02-24 |
| CA2750944A1 (en) | 2010-08-05 |
| PT2391363T (pt) | 2016-12-23 |
| SI2391363T1 (sl) | 2017-01-31 |
| EP2391363B1 (en) | 2016-09-28 |
| AU2010208062A1 (en) | 2011-08-18 |
| JP2015180680A (ja) | 2015-10-15 |
| PL2391363T3 (pl) | 2017-03-31 |
| ES2607211T3 (es) | 2017-03-29 |
| WO2010088564A3 (en) | 2010-12-29 |
| HUE032389T2 (en) | 2017-09-28 |
| EP2391363A4 (en) | 2012-09-19 |
| IL214349A0 (en) | 2011-09-27 |
| IL214349A (en) | 2015-02-26 |
| CN102387801A (zh) | 2012-03-21 |
| AU2010208062B2 (en) | 2014-07-24 |
| CA3024263A1 (en) | 2010-08-05 |
| DK2391363T3 (en) | 2017-01-16 |
| CA2750944C (en) | 2019-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012018949A3 (en) | Compositions and methods for the treatment of cancer | |
| WO2010088564A3 (en) | Compositions and methods for the treatment of cancer | |
| WO2022006184A3 (en) | Cellular energy inhibitor formulations for the treatment of pathogenic infections and associated methods | |
| TN2012000109A1 (en) | Glycoside derivatives and uses thereof | |
| NZ600119A (en) | Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives | |
| GEP20135991B (en) | 2-carboxamide-pyrrolidine-amide urea derivatives substituted with pyrimidine-4-yl, and usage thereat treatment of diseases caused by phosphatidyl inositol 3-kinase | |
| PH12018500696A1 (en) | Personal cleansing compositions and methods of stabilizing the miccrobiome | |
| AU2010230585A8 (en) | Autotaxin inhibitors | |
| UA108219C2 (uk) | Протипаразитарні дигідроазолові сполуки та композиція, яка їх містить (варіанти) | |
| MY159252A (en) | Process for the preparation of dopo-derived compounds and compositions thereof | |
| RU2012150279A (ru) | Гранулы фермента | |
| MY157126A (en) | Composition for metal plating comprising suppressing agent for void free submicron feature filling | |
| WO2011048148A3 (en) | Glycoside derivative and uses thereof | |
| MX2009006256A (es) | Composiciones intensificadoras inhibidoras de corrosion y metodos relacionados. | |
| MX2013005529A (es) | Composicion conservadora concentrada acuosa y estable de acido deshidroacetico (dha) y metilisotiazolinona. | |
| DE602007008389D1 (de) | Synthese von phenolischen estern von hydroxymethylphenolen | |
| JP2014526586A5 (enExample) | ||
| RU2011144851A (ru) | Соли 6'-сиалиллактозы и способ их синтеза и синтеза других а-сиалилолигосахаридов | |
| MX2014002314A (es) | Producto de yeso anticombado y un procedimiento de fabricacion. | |
| GEP20115166B (en) | 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS | |
| DE50105454D1 (de) | Verfahren zur katalytischen Reduktion von Alkinverbindungen | |
| MX2011011849A (es) | Proceso para la preparacion de un compuesto util como inhibidor de tafia. | |
| EA201071425A1 (ru) | Соли карбоновой кислоты 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина | |
| MY159304A (en) | Detergent composition | |
| MY163294A (en) | Skin cleanser composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AABA | Application abandoned | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 JAN 2017 BY NZMARKS LTD Effective date: 20150702 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2018 BY COMPUTER PACKAGES INC Effective date: 20170118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2019 BY COMPUTER PACKAGES INC Effective date: 20180118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2020 BY COMPUTER PACKAGES INC Effective date: 20190219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2021 BY COMPUTER PACKAGES INC Effective date: 20200118 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2022 BY COMPUTER PACKAGES INC Effective date: 20201231 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2023 BY COMPUTER PACKAGES INC Effective date: 20220130 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2024 BY COMPUTER PACKAGES INC Effective date: 20221230 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2025 BY COMPUTER PACKAGES INC Effective date: 20240117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 29 JAN 2026 BY COMPUTER PACKAGES INC Effective date: 20250117 |